ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows

ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows
OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines — molecules produced by immune cells — interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The clinical trial (NCT02058680) is evaluating

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *